Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison.
暂无分享,去创建一个
Ute Hofmann | Mathias Haag | Falko Fend | Denise Sonntag | Judith Wahrheit | Stefan Winter | Jörg Hennenlotter | U. Hofmann | M. Haag | M. Schwab | F. Fend | S. Winter | E. Schaeffeler | J. Bedke | S. Rausch | J. Hennenlotter | J. Wahrheit | T. Mürdter | Matthias Schwab | Elke Schaeffeler | Patrick Leuthold | F. Büttner | D. Sonntag | Jens Bedke | Florian Büttner | Steffen Rausch | Patrick Leuthold | Thomas E Mürdter
[1] Cristina Bianchi,et al. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. , 2015, Cancer research.
[2] Xin Lu,et al. Multiple reaction monitoring-ion pair finder: a systematic approach to transform nontargeted mode to pseudotargeted mode for metabolomics study based on liquid chromatography-mass spectrometry. , 2015, Analytical chemistry.
[3] Anthony B. Costa,et al. Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry , 2010, Analytical and bioanalytical chemistry.
[4] Otto Savolainen,et al. A Simultaneous Metabolic Profiling and Quantitative Multimetabolite Metabolomic Method for Human Plasma Using Gas-Chromatography Tandem Mass Spectrometry. , 2016, Journal of proteome research.
[5] M. Schwab,et al. DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome , 2013, Clinical Cancer Research.
[6] Caroline H. Johnson,et al. Metabolomics: beyond biomarkers and towards mechanisms , 2016, Nature Reviews Molecular Cell Biology.
[7] Xiaomei Yan,et al. Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. , 2010, The Analyst.
[8] Joachim Selbig,et al. Metabolic profiling reveals key metabolic features of renal cell carcinoma , 2009, Journal of cellular and molecular medicine.
[9] P. Humphrey,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.
[10] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[11] Arndt Hartmann,et al. Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. , 2015, European urology.
[12] Oliver Fiehn,et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling , 2006, Molecular Cancer.
[13] T. Spector,et al. Genetic Influences on Metabolite Levels: A Comparison across Metabolomic Platforms , 2016, PloS one.
[14] Chris Sander,et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. , 2016, Cancer cell.
[15] A. Davies,et al. Untargeted UPLC-MS Profiling Pipeline to Expand Tissue Metabolome Coverage: Application to Cardiovascular Disease , 2015, Analytical chemistry.
[16] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[17] T. Mak,et al. Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.
[18] R. Murphy,et al. Electrospray ionization tandem mass spectrometry of glycerophosphoethanolamine plasmalogen phospholipids , 2004, Journal of the American Society for Mass Spectrometry.
[19] Xiaomei Yan,et al. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. , 2011, Journal of proteome research.
[20] U. Hofmann,et al. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na+-taurocholate cotransporting polypeptide inhibitor , 2015, Analytical and Bioanalytical Chemistry.
[21] M. Snyder,et al. Can Metabolic Profiles Be Used as a Phenotypic Readout of the Genome to Enhance Precision Medicine? , 2016, Clinical chemistry.
[22] Oliver Fiehn,et al. Toward Merging Untargeted and Targeted Methods in Mass Spectrometry-Based Metabolomics and Lipidomics. , 2016, Analytical chemistry.
[23] M. Haag,et al. Quantification of Signaling Lipids by Nano-Electrospray Ionization Tandem Mass Spectrometry (Nano-ESI MS/MS) , 2012, Metabolites.
[24] Ralf Tautenhahn,et al. Toward 'omic scale metabolite profiling: a dual separation-mass spectrometry approach for coverage of lipid and central carbon metabolism. , 2013, Analytical chemistry.
[25] H. Fujii,et al. Analysis of Renal Cell Carcinoma as a First Step for Developing Mass Spectrometry-Based Diagnostics , 2012, Journal of The American Society for Mass Spectrometry.
[26] M. Barrett,et al. Enhanced Acylcarnitine Annotation in High-Resolution Mass Spectrometry Data: Fragmentation Analysis for the Classification and Annotation of Acylcarnitines , 2015, Front. Bioeng. Biotechnol..
[27] M. T. Donato,et al. A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations. , 2011, Journal of proteome research.
[28] M. Hirai,et al. MassBank: a public repository for sharing mass spectral data for life sciences. , 2010, Journal of mass spectrometry : JMS.
[29] R. Murphy,et al. Detection of the abundance of diacylglycerol and triacylglycerol molecular species in cells using neutral loss mass spectrometry. , 2007, Analytical biochemistry.
[30] Xin Lu,et al. Optimization of large-scale pseudotargeted metabolomics method based on liquid chromatography-mass spectrometry. , 2016, Journal of chromatography. A.
[31] C. Barbas,et al. Rapid and Reliable Identification of Phospholipids for Untargeted Metabolomics with LC-ESI-QTOF-MS/MS. , 2015, Journal of proteome research.
[32] Lihua Jiang,et al. Optimized Analytical Procedures for the Untargeted Metabolomic Profiling of Human Urine and Plasma by Combining Hydrophilic Interaction (HILIC) and Reverse-Phase Liquid Chromatography (RPLC)–Mass Spectrometry* , 2015, Molecular & Cellular Proteomics.
[33] Yiran Huang,et al. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. , 2008, Analytica chimica acta.
[34] J. Peter-Katalinic,et al. On-line nano-HPLC/ESI QTOF MS monitoring of α2–3 and α2–6 sialylation in granulocyte glycosphingolipidome , 2009, Biological chemistry.
[35] M. Carvalho,et al. Biomarkers in renal cell carcinoma: a metabolomics approach , 2014, Metabolomics.
[36] Antonio Lopez-Beltran,et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. , 2015, European urology.
[37] T. Ebbels,et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts , 2007, Nature Protocols.
[38] K. Yamaguchi,et al. Plasma Membrane-associated Sialidase Is Up-regulated in Renal Cell Carcinoma and Promotes Interleukin-6-induced Apoptosis Suppression and Cell Motility* , 2006, Journal of Biological Chemistry.
[39] K. Michalak,et al. Key Roles of Glutamine Pathways in Reprogramming the Cancer Metabolism , 2015, Oxidative medicine and cellular longevity.
[40] I. Wilson,et al. A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. , 2006, The Analyst.
[41] Jerzy Adamski,et al. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics , 2011, Metabolomics.
[42] M. Perazella,et al. The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. , 2016, Journal of the American Society of Nephrology : JASN.
[43] T. Ebbels,et al. Optimization and evaluation of metabolite extraction protocols for untargeted metabolic profiling of liver samples by UPLC-MS. , 2010, Analytical chemistry.
[44] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[45] Taka-Aki Sato,et al. Structural characterization of neutral glycosphingolipids using high-performance liquid chromatography-electrospray ionization mass spectrometry with a repeated high-speed polarity and MSn switching system , 2013, Glycoconjugate Journal.
[46] Sejong Bae,et al. A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody , 2014 .
[47] Oliver Fiehn,et al. A comprehensive urinary metabolomic approach for identifying kidney cancerr. , 2007, Analytical biochemistry.
[48] Christian Gieger,et al. Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting , 2010, PloS one.
[49] Y. Kanai,et al. Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma , 2016, Scientific Reports.
[50] R. Abagyan,et al. METLIN: A Metabolite Mass Spectral Database , 2005, Therapeutic drug monitoring.
[51] David S. Wishart,et al. MetaboAnalyst 3.0—making metabolomics more meaningful , 2015, Nucleic Acids Res..
[52] Tomasz Burzykowski,et al. Evaluation of normalization methods to pave the way towards large-scale LC-MS-based metabolomics profiling experiments. , 2013, Omics : a journal of integrative biology.
[53] J. Borén,et al. Increased Expression of the Very Low-Density Lipoprotein Receptor Mediates Lipid Accumulation in Clear-Cell Renal Cell Carcinoma , 2012, PloS one.
[54] David S. Wishart,et al. HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..
[55] E. Mikros,et al. (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. , 2010, Journal of proteome research.
[56] Eoin Fahy,et al. LIPID MAPS online tools for lipid research , 2007, Nucleic Acids Res..
[57] M. Schwab,et al. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. , 2013, Trends in pharmacological sciences.
[58] R. Weiss,et al. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. , 2011, Omics : a journal of integrative biology.
[59] Kyoungmi Kim,et al. Urine Metabolomics Analysis for Kidney Cancer Detection and Biomarker Discovery*S , 2009, Molecular & Cellular Proteomics.
[60] Julie Klein,et al. Assessment of Metabolomic and Proteomic Biomarkers in Detection and Prognosis of Progression of Renal Function in Chronic Kidney Disease , 2014, PloS one.
[61] B. Melichar,et al. Lipidomic differentiation between human kidney tumors and surrounding normal tissues using HILIC-HPLC/ESI-MS and multivariate data analysis. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[62] Yiran Huang,et al. Application of ex vivo 1H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases , 2012, Journal of Cancer Research and Clinical Oncology.